{
    "ticker": "ZMENY",
    "name": "Zynerba Pharmaceuticals, Inc.",
    "description": "Zynerba Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative transdermal cannabinoid treatments for patients with debilitating neuropsychiatric conditions. Founded in 2007, Zynerba is at the forefront of cannabinoid research, leveraging its proprietary Zygel\u2122 transdermal delivery system to provide patients with effective and non-invasive treatments. The company\u2019s lead product candidate, Zygel, is currently in clinical trials for the treatment of Fragile X Syndrome and other neuropsychiatric disorders. Zynerba aims to address significant unmet medical needs by providing patients with cannabinoid therapies that are safe, effective, and easy to use. The company's commitment to research and development is complemented by collaborations with academic institutions and industry partners to advance its pipeline of cannabinoid products. Zynerba\u2019s mission is to improve the quality of life for patients suffering from serious and chronic conditions through the power of the endocannabinoid system.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Devon, Pennsylvania, USA",
    "founded": "2007",
    "website": "https://www.zynerba.com",
    "ceo": "Armando Anido",
    "social_media": {
        "twitter": "https://twitter.com/zynerbapharma",
        "linkedin": "https://www.linkedin.com/company/zynerba-pharmaceuticals-inc/"
    },
    "investor_relations": "https://investors.zynerba.com",
    "key_executives": [
        {
            "name": "Armando Anido",
            "position": "CEO"
        },
        {
            "name": "Michael McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cannabinoid Treatments",
            "products": [
                "Zygel"
            ]
        }
    ],
    "seo": {
        "meta_title": "Zynerba Pharmaceuticals, Inc. | Innovative Cannabinoid Treatments",
        "meta_description": "Explore Zynerba Pharmaceuticals, Inc., a leader in transdermal cannabinoid therapies aimed at treating neuropsychiatric conditions. Discover our innovative products and commitment to patient care.",
        "keywords": [
            "Zynerba",
            "Cannabinoid Treatments",
            "Zygel",
            "Neuropsychiatric Disorders",
            "Biopharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Zynerba Pharmaceuticals known for?",
            "answer": "Zynerba Pharmaceuticals is known for developing transdermal cannabinoid treatments for neuropsychiatric conditions."
        },
        {
            "question": "Who is the CEO of Zynerba Pharmaceuticals?",
            "answer": "Armando Anido is the CEO of Zynerba Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Zynerba headquartered?",
            "answer": "Zynerba is headquartered in Devon, Pennsylvania, USA."
        },
        {
            "question": "What is Zynerba's lead product?",
            "answer": "Zynerba's lead product candidate is Zygel, which is in clinical trials for treating Fragile X Syndrome."
        },
        {
            "question": "When was Zynerba founded?",
            "answer": "Zynerba was founded in 2007."
        }
    ],
    "competitors": [
        "GWPH",
        "CRON",
        "ACB"
    ],
    "related_stocks": [
        "ACAD",
        "VRTX",
        "REGN",
        "NVS"
    ]
}